Research | Clinical Trials | Clinical Trial Details Page

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

Conditions

Schizoaffective Disorder | Schizophrenia

Trial Phase

Phase 2

Trial Purpose and Description

Trial Purpose

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.


Participation Guidelines

Age:
18 Years - 65 Years
Gender:
Both

Eligibility Criteria


Inclusion Criteria:

- Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),

Exclusion Criteria:

- Women who are pregnant, nursing or unwilling to use appropriate birth control
measures during study participation.
Sponsor:
Stanley Medical Research Institute
Yale University
Dates:
February 2009
Last Updated:
August 10, 2010
Study HIC#:
0710003164

Clinicaltrials.gov ID: NCT00588731